First quarter earnings for Gilead Sciences Inc. (Nasdaq: GILD) surged to 92 cents per share from 63 cents per share in the year ago period to top analyst estimates but the biopharmaceutical lowered its 2010 revenue outlook. The stock price plunged $4.52 to $40.55.
Gilead Lowers Outlook
April 21, 2010 at 12:13 PM EDT
